FAKTOR OPTIONSSCHEIN - MODERNA | Real-time BOERSE MUENCHEN 03:00:47 2024-06-17 EDT | ||
| 1.36 EUR | +4.94% |
|
| Current month | -6.90% | ||
| 1 month | +10.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 1.36 | +4.94% |
| 24-06-14 | 1.296 | -13.77% |
| 24-06-13 | 1.503 | -6.82% |
| 24-06-12 | 1.613 | +0.50% |
| 24-06-11 | 1.605 | +2.69% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 03:00 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GK48ZE |
| ISIN | DE000GK48ZE9 |
| Date issued | 2022-05-12 |
| Strike | 93.35 $ |
| Maturity | Unlimited |
| Parity | 30.29 : 1 |
| Emission price | 9.36 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.47 € |
|---|---|
| Lowest since issue | 0.308 € |
| Spread | 0.01 € |
| Spread % | 0.74% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat
